Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 162

1.

Discrepancies between upper GI symptoms described by those who have them and their identification by conventional medical terminology: a survey of sufferers in four countries.

Heading RC, Thomas EC, Sandy P, Smith G, Fass R, Hungin PS.

Eur J Gastroenterol Hepatol. 2016 Apr;28(4):455-62. doi: 10.1097/MEG.0000000000000565.

2.

Gastroesophageal and extraesophageal reflux symptoms: similarities and differences.

Drinnan M, Powell J, Nikkar-Esfahani A, Heading RC, Doyle J, Griffin SM, Leslie P, Bradley PT, James P, Wilson JA.

Laryngoscope. 2015 Feb;125(2):424-30. doi: 10.1002/lary.24950. Epub 2014 Sep 30.

PMID:
25267601
3.

Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial.

Faria R, Bojke L, Epstein D, Corbacho B, Sculpher M; REFLUX trial group.

Br J Surg. 2013 Aug;100(9):1205-13. doi: 10.1002/bjs.9190. Epub 2013 Jun 17.

PMID:
23775366
4.

Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial).

Grant AM, Boachie C, Cotton SC, Faria R, Bojke L, Epstein DM, Ramsay CR, Corbacho B, Sculpher M, Krukowski ZH, Heading RC, Campbell MK; REFLUX trial group.

Health Technol Assess. 2013 Jun;17(22):1-167. doi: 10.3310/hta17220.

5.

Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX).

Grant AM, Cotton SC, Boachie C, Ramsay CR, Krukowski ZH, Heading RC, Campbell MK; REFLUX Trial Group.

BMJ. 2013 Apr 18;346:f1908. doi: 10.1136/bmj.f1908.

6.

Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.

Mönnikes H, Heading RC, Schmitt H, Doerfler H.

World J Gastroenterol. 2011 Jul 21;17(27):3235-41. doi: 10.3748/wjg.v17.i27.3235.

7.

Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.

Heading RC, Mönnikes H, Tholen A, Schmitt H.

BMC Gastroenterol. 2011 May 11;11:52. doi: 10.1186/1471-230X-11-52.

8.

Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study.

Epstein D, Bojke L, Sculpher MJ; REFLUX trial group.

BMJ. 2009 Jul 14;339:b2576. doi: 10.1136/bmj.b2576.

9.

Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.

Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Heading RC, Holtman G, Moss SF; Vevey NERD Consensus Group.

Digestion. 2009;80(2):74-88. doi: 10.1159/000219365. Epub 2009 Jun 17.

10.

A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.

Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kato H.

Neurogastroenterol Motil. 2009 Mar;21(3):272-80. doi: 10.1111/j.1365-2982.2009.01261.x.

11.

Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial.

Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, Thursz MR, Campbell MK; REFLUX Trial Group.

BMJ. 2008 Dec 15;337:a2664. doi: 10.1136/bmj.a2664.

12.

Non-erosive reflux disease--some clinical case scenarios.

Heading RC.

Digestion. 2008;78 Suppl 1:55-60. doi: 10.1159/000151256. Epub 2008 Oct 2.

PMID:
18832841
13.

The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group.

Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv.

14.

The nonerosive reflux disease-gastroesophageal reflux disease controversy.

Winter JW, Heading RC.

Curr Opin Gastroenterol. 2008 Jul;24(4):509-15. doi: 10.1097/MOG.0b013e3283025c57. Review.

PMID:
18622168
15.

Validation of a brief symptom questionnaire (ReQuest in Practice) for patients with gastro-oesophageal reflux disease.

Rubin G, Uebel P, Brimo-Hayek A, Hey KH, Doerfler H, Heading RC.

Aliment Pharmacol Ther. 2008 May;27(9):846-51. doi: 10.1111/j.1365-2036.2008.03641.x. Epub 2008 Feb 9.

16.

Whistler summary: "the slow rate of rapid progress".

Hunt RH, Tytgat GH, Malfertheiner P, Fock KM, Heading RC, Katelaris PH, McCarthy DM, McColl KE, Moss SF, Sachs G, Sontag SJ, Thomson AB, Modlin IM.

J Clin Gastroenterol. 2007 Jul;41(6):539-45. No abstract available.

PMID:
17577108
17.

Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal.

Davies NM, Grinyó J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M.

Nephrol Dial Transplant. 2007 Sep;22(9):2440-8. Epub 2007 Jun 8. Review.

18.

Debate: endoscopy is unnecessary in the management of uncomplicated GERD.

Heading RC, Spechler S, Malfertheiner P.

Drugs Today (Barc). 2006 Jul;42 Suppl B:15-21.

PMID:
16986067
19.

Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.

Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G.

Aliment Pharmacol Ther. 2006 Jul 15;24(2):207-36. Review.

20.

Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil.

Meier-Kriesche HU, Davies NM, Grinyó J, Heading R, Mamelok R, Wijngaard P, Oellerich M, Maes B.

Am J Transplant. 2005 May;5(5):1164; author reply 1165-6. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk